Collegium Pharmaceutical (COLL)

Its pain franchise includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties, and the Nucynta products, which include immediate-release and extended-release tapentadol formulations. Collegium also markets Belbuca, a buprenorphine buccal film used for chronic pain severe enough to require around-the-clock opioid treatment, and Symproic, a treatment for opioid-induced constipation in adults with chronic non-cancer pain. In ADHD, the company commercializes Jornay PM, a methylphenidate product designed for evening dosing so that symptom control can begin in the morning.

Collegium’s business model is centered on commercial execution in the United States, careful lifecycle management, and disciplined portfolio expansion. Because several of its products are used in regulated areas of medicine, the company operates in markets shaped by prescribing rules, payer coverage, generic competition, and heightened scrutiny of opioid therapies. Its performance depends on prescription trends, formulary access, physician adoption, product exclusivity, and the ability to manage compliance in complex therapeutic categories. For investors, Collegium stands out as a profitable specialty pharma platform with a concentrated but diversified set of branded medicines addressing pain-related conditions and ADHD.